Research

The Role of Positive Thinking

The Physical Aspect

A positive attitude can increase the body’s immunological response to disease, as evidenced by alterations in serum proteins, antibody production, and the organism’s total immune response. Patients should be advised that their bodies need the help and stimulation of positive attitudes and optimistic thoughts.

The patient’s co-operative effort in taking responsibility for his diet and hygiene, for taking the Vitamin B-17 tablets and the enzymes, for follow-up diagnostic tests, and for acting positively on his own behalf is essential to the most complete controlling possible of his cancer. If the patient’s attitude is uncooperative or negative with the continued use of tobacco, cigarettes, or exposure to known occupational carcinogenic environment, the patient should be dealt with in a forthright manner. Negative attitudes should be thoroughly discouraged.

The negativism associated with the majority of cancer patients prior to Vitamin B-17 therapy is one of the corrections, which may be brought about in the course of this therapy. Persistent negative attitude and failure to improve may indicate that the dosage is too small or too infrequent.

The Psychological Aspect

“The mind, the emotions, and the attitude of a patient play a role in both the development of a disease, cancer included, and the response that a patient has to any form of treatment.” (Air Force Major O. Carl Simonton, M.D.)

The onset of cancer may be correlated with major crises previously occurring at both social levels and deep personal levels of life experience, characteristically the loss of personal orientation or ego diminishment brought on by major disruptions such as occupational or social reversals, bereavement or deprivation, divorce. As such, cancer may appear in the self-defeating patient as “a form of socially acceptable suicide.”

Self-defeating attitudes should be recognised by the physician, who may indicate to the patient that he is using his illness to further his personal psychological objectives, and this is why his thinking and behaviour remains negative in spite of objective gains of the therapy.

Patients (and their families) should also be encouraged to carry on or develop interests outside of their illness as indeed the majority of successful patients do, since with Vitamin B-17 therapy many are relieved of the continual reminder of cancer by the relief of pain and the reduction of other symptoms.

REFERENCES

  • Clinical Oncology for Medical Students and Physicians, op. cit, pp.32 , 34
  • Spontaneous Regression of Cancer: “The Metabolic Triumph of the Host!”, op. cit.,pp. 136, 137.
  • Manner, HW, Michaelson, TL, and DiSanti, SJ. “Enzymatic Analysis of Normal and Malignant Tissues.” Presented at the Illinois State Academy of Science, April 1978. Also, Manner, HW, Michaelson, TL, and DiSanti, SJ, “Amygdalin, Vitamin A and Enzymes Induced Regression of Murine Mammary Adenocarcinomas”, Journal of Manipulative and Physiological Therapeutics, Vol 1, No. 4, December 1978. 200 East Roosevelt Road, Lombard, IL 60148 USA
  • Vitamin B15 (Pangamic Acid); Properties, Functions, and Use. (Moscow: Science Publishing House, 1965), translated and reprinted by McNaughton Foundation, Sausalito, Calif.
  • Catalona, et al. Medical World News, 6/23/72, pg 82M California cancer Advisory council, 1963, pg 10 Weilerstein, R. W., ACS Volunteer, 19, #1, 1973
  • Burger, Hospital Practice, July, 1973, 55-62
  • Currie & Bagshawe, Lancet, 1, (7492), 708, 1967
  • Abercrombie, Ca. Res. 22, 525, 1962
  • Cormack, Ca. Res. 30, (5), 1459, 1970
  • catalona, et al. Medical World News, 6/23/72, pg 82M
  • Jose, Nut. Today, March, 1973, pgs 4-9
  • Burk & Winzler, VITAMINS AND HORMONES, vol. II, 1944
  • Adcock et al, Science, 181, 8/31/73, 845-47
  • Dr. Dean Burk formerly chief of cytochemistry, The National cancer institute, and Dr. John Yiamouyiannis, Science Director of The National Health Federation, Formerly an editor of chemical Abstracts.
  • Fairley, Brit. Med. J. 2,1969, 467-473
  • Burk, McNaughton, Von Ardenne, PanMinerva Med. 13, #12, Dec. 1971
  • Lea, et al, ca. Res. 35, 2321 -2326, Sept. 1975
  • The McNaughton Foundation, I.N.D. 6734, April 6, 1970
  • Nieper, Krebsgeschehen, 4,1972
  • J.A.M.A. 225, 4, July, 1973, pg 424
  • Shamberger et al, Proc. Nat, Acad. Sci. May, 1973
  • Shute & Shute, ALPHA TOCOPHEROL IN CARDIOVASCULAR DISEASE, Ryerson Press, Toronto, Canada, 1954
  • Ransberger, 10th Int. Cancer Congress, 1970
  • Wolf & Ransberger, ENZYME THERAPY, Vantage Pr. 1972
  • Summa; DipI. Ing. (chem) Landstuhl, 1972
  • Reitnauer, Arzneim. Forsch. 22, 1347-61, 1972
  • Folkman, Ann. Surg. 175, (3). 409-1 6, 1972
  • Penn, 7th Annual Cancer Conf. 1973
  • The MEDICAL LETTER, vol. 15, #3 (issue #367) 2/2/73
  • Kreuger, ADVANCES IN PHARM. & CHEMOTHERAPY, vol x, 1973
  • Prejean & Griswold, NCI Progress Rep. (So. Res. Inst.) 9/72
  • Annals New York Academy of Science: 164, 2, 1969
  • Sorbo, Acta Chem. Scand. 5, 1951, (724-34); 1953 (1129-1136); 1953 (1137-1145)
  • Clemedson et al, Acta Physiol. Scand. 32, 1954, 245
  • Engel, Med. Klink. 20, 1790, 1930
  • DeFermo, Arch. Ital. de Chir. 33: 801, 1933
  • Saphir,~Endocrinol. 18, 191, 1934
  • Velasquez & Engel, Endocrinol. 27, 523, 1940
  • Li, Med. Clin N. Am. 45, 661 -666, May, 1961
  • Roffo, Bol. Inst. de Med. 21, 41 9-586, 1944
  • Friedman, Ann. N.Y. Acad. Sci. 80-1 61, 1959 (and refs)
  • Krebs & Gurchot, Science, 104, 302, 1946
  • Braunstein, et al, Annals Int. Med. 78:39-45, 1973
  • Naughton et al, Ca. Res. 35, 1887-1 890, July, 1975
  • Wide & Gemzell, Acta Endocrinol. 35-261, 1960
  • Navarro, 9th International Cancer Congress, Toyko, Oct. 1966 reported in HEALTH AND LIGHT, by John Ott, D.Sc., Devin Adair, 1973
  • Nieper, Agressologie 12, 6,1971, 401-8
  • Livingston, CANCER: A NEW BREAKTHROUGH, Nash Publishing, Los Angeles, 1972
  • Benno C. Schmidt, chairman of the Memorial Sloan-Kettering Cancer Center, New York City, chairman of The President’s Cancer Panel; address to the A.C.S., California Division, Oct. 12, 1973 (Los Angeles Times)
  • Yudkin, SWEET AND DANGEROUS, Bantam Books, 1972
  • Seminars on Healing, The Academy of Parapsychology and Medicine, June 1973
  • Torrance & Schnabel, Ann. Intern. Med. 6, 732, 1932
  • Leivy & Schnabel, Am. I. Med. Sd. 183, 381, 1932
  • Gillette, et al, I. Clin. Invest. 51, 36a, 1972
  • Gillette, et al, New Eng. J. Med. 290, 654, 1974
  • Cerami & Manning, Prac. NatI. Acad. Sci. 68, 1180, 1971
  • Gillette et al, ibid, 68, 2791, 1971
  • Cerami, et al, Fed. Proc. 32, 1668, 1973
  • Manning, et al, Adv. Exp. Med. Biol. 28, 253, 1972
  • Houston, Am. Laboratory, 7, #10, October, 1975 (and editorial)
  • DeLange & Ermans, Am. I. Clin. Nut. 24, 1354, 1971
  • Barnes, Broda, M.D., HEART ATTACK RARENESS IN THYROID-TREATED PA TIENTS, C.C. Thomas, 1972
  • Barnes and Galton, HYPOTHYROIDISM, THE UNSUSPECTED ILLNESS, Thomas Y. Crowell, N.Y., Feb. 1976
  • Smith, J. C. Medical Counterpoint, Nov. 1973
  • Oberleas, lntntl. Trace Elements Symp. Modern Med., Sept. 16, 1974
  • New Scientist, 5/2/74
  • Korant, B.D., Nature, 4/12/74
  • Klenner, FR., I. So. Med. & Surg. 111, 209, 1949
  • Stacpoole, P.W., Med. Hyp., March-April, 1975


ACKNOWLEDGMENTS

This web-site is the result of a compendium of more than 70 years experience with Vitamin B-17, culled from writings and communications of the following doctors and scientists:

Dr Ernest T. Krebs, jr. Ph.D., D.Sc.
Dr Ernest T. Krebs, Sr. M.D.
Dr N. R. Bouziane, M.D.
Dr Dean Burk, Ph.D.
Dr Ernesto Contreras, M.D.
Dr Francisco Contreras, M.D.
Dr. Harold Manner, M.D.
Dr. Philip Binzel, M.D.
Dr Christian Deckers, M.D.
Dr Ettore Guidetti, M.D.
Dr Charles Gurchot, Ph.D.
Dri. D. Hamilton, M.D.
Dr Maurice Kowan, M.D.
Dr I. Maisin, jr. M.D.
Dr I. Maisin, sr. M.D.
Dr Leon Lewis, M.D.
Dr John A. Morrone, M.D.
Dr Manuel Navarro, M.D.
Dr Hans A. Nieper, M.D.
Edward Spicer, esq.
Dr Emory Thurston, Ph.D., D.Sc.
Dr Prof. Manfred Von Ardenne
Dr. John A. Richardson, M.D.

And many other physicians and scientists whose contributions since the early 1920’s laid the groundwork for the present state of the art of physiological management of the metabolic disease of cancer with Vitamin
B-17.